ABSTRACT
Revisión sistemática exploratoria para describir el conocimiento existente en la relación entre la exposición al humo quirúrgico y los efectos negativos sobre la salud de los trabajadores expuestos. Concretar los tóxicos y/o agentes biológicos que se pueden encontrar en el humo quirúrgico. Se realizó búsqueda bibliográfica de artículos científicos en las siguientes bases de datos: MEDLINE (a través de Pubmed), LILACS, IBECS, Red SCIELO, BIBLIOTECA COCHRANE. Se recuperaron un total de 312 artículos. Después de aplicar los criterios de inclusión, quedó una colección de 15. El humo quirúrgico contiene tóxicos volátiles, cancerígenos, mutágenos y microorganismos, y su inhalación constituye un potencial riesgo químico y biológico para la salud de los trabajadores involucrados en las cirugías. Se podrían generar nuevas hipótesis de investigación más profundas en algunos ámbitos de exposición crónica. (AU)
Exploratory systematic review to describe the existing knowledge of the relationship between exposure to surgical smoke and negative effects on the health of exposed workers. Specify the toxins and/or biological agents that can be found in surgical smoke. A bibliographic search of scientific articles was carried out in the following databases: MEDLINE (through Pubmed), LILACS, IBECS, Red SCIELO, LIBRARY COCHRANE. A total of 312 articles were retrieved. After applying the inclusion criteria, a collection of 15 remained. Surgery smoke contains toxic volatiles, carcinogenic, mutagenic compounds and microorganisms, and its inhalation constitutes a potential chemical and biological risk to the health of workers involved in surgeries. New deeper research hypotheses could be generated in some areas of chronic exposure. (AU)
Subject(s)
Humans , History, 21st Century , Smoke , Occupational Risks , Occupational Health , Toxic Substances , General SurgeryABSTRACT
The clinical utility of minimal residual disease (MRD) analysis in acute myeloid leukaemia (AML) is not yet defined. We analysed the prognostic impact of MRD level at complete remision after induction therapy using multiparameter flow cytometry in 306 non-APL AML patients. First, we validated the prognostic value of MRD-thresholds we have previously proposed (≥ 0.1%; ≥ 0.01-0.1%; and <0.01), with a 5-year RFS of 38%, 50% and 71%, respectively (p=0.002). Cytogenetics is the most relevant prognosis factor in AML, however intermediate risk cytogenetics represent a grey zone that require other biomarkers for risk stratification, and we show that MRD evaluation discriminate three prognostic subgroups (p=0.03). Also, MRD assessments yielded relevant information on favourable and adverse cytogenetics, since patients with favourable cytogenetics and high MRD levels have poor prognosis and patients with adverse cytogenetics but undetectable MRD overcomes the adverse prognosis. Interestingly, in patients with intermediate or high MRD levels, intensification with transplant improved the outcome as compared with chemotherapy, while the type of intensification therapy did not influenced the outcome of patients with low MRD levels. Multivariate analysis revealed age, MRD and cytogenetics as independent variables. Moreover, a scoring system, easy in clinical practice, was generated based on MRD level and cytogenetics.
Subject(s)
Leukemia, Myeloid, Acute/therapy , Neoplasm, Residual , Aged , Chromosome Aberrations , Flow Cytometry , Humans , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/pathology , Middle AgedABSTRACT
BACKGROUND: Few studies have evaluated the risk of pregnancy-related adverse events in asymptomatic relatives of probands for VTE and factor V Leiden or the G20210A variant. The antepartum management of this population ranges from antepartum anticoagulation therapy to clinical surveillance. OBJECTIVE: To evaluate the risk of placenta-mediated pregnancy complications and pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and who are heterozygous carriers of either factor V Leiden or PT-G20210A mutation. METHODS: One hundred and fifty-eight relatives, who had 415 pregnancies, were retrospectively evaluated. Odds ratios and 95% confidence intervals were calculated to compare pregnancy outcomes between women with and without thrombophilia. RESULTS: In the factor V Leiden group, 22 placenta-mediated pregnancy events of 152 pregnancies (14.4%) were reported, compared with 25 adverse events of 172 pregnancies in the G20210A prothrombin group (14.5%) and 13 adverse events of 91 pregnancies in the non-carrier group (14.2%). Carriers of factor V Leiden or G20210A prothrombin were not associated with a higher risk of pregnancy-adverse outcomes compared with non-carriers: OR 1.02 (95% CI, 0.40-2.25) and 1.25 (95% CI, 0.48-3.24), respectively. Four episodes of pregnancy-associated VTE of 415 pregnancies (0.96%) were recorded. Two episodes of VTE in the G20210A group, one in the factor V Leiden group, and one episode in the non-carrier group were noted. CONCLUSIONS: In VTE-asymptomatic relatives of probands with VTE, the presence of factor V Leiden or the G20210A prothrombin mutation in heterozygosis should not lead to a decision to instigate antepartum prophylaxis.
Subject(s)
Factor V/genetics , Heterozygote , Mutation , Placenta/physiopathology , Pregnancy Complications, Hematologic/physiopathology , Prothrombin/genetics , Venous Thromboembolism/complications , Female , Humans , Pregnancy , Pregnancy Complications, Hematologic/genetics , Venous Thromboembolism/geneticsABSTRACT
Existe una estrecha asociación entre cáncer y sistema hemostático. El dímero-D (DD) es un marcador de generación y posterior degradación de fibrina, cuya principal aplicación en la práctica clínica habitual se enmarca dentro de los algoritmos diagnósticos de la enfermedad tromboembólica venosa (ETV) y en los criterios diagnósticos para establecer una coagulación intravascular diseminada. La utilidad del DD en el diagnóstico de la ETV en pacientes con cáncer parece ser inferior debido a la menor especificidad en este tipo de pacientes. Sin embargo, existe una creciente evidencia sobre el papel del DD en los pacientes con cáncer como indicador del riesgo de sufrir un episodio de ETV, marcador de la posible existencia de una neoplasia oculta en pacientes con ETV idiopática o incluso como factor pronóstico independiente de respuesta al tratamiento quimioterápico y de supervivencia. En esta revisión se analiza la evidencia que avala la utilización del DD en el contexto clínico del cáncer (AU)
There is a well-known close relationship between cancer and the haemostatic system. Plasma D-dimer (DD) is a marker of fibrin generation and lysis. In the clinical practice, its main use is in the diagnostic algorithms of venous thromboembolism (VTE), and it is one of the diagnostic criteria of disseminated intravacular coagulation. In patients with cancer, the specificity of DD is lower than in the general population, reducing its usefulness. However, there is a growing evidence that points out a possible application of DD in the clinical management of cancer patients as a predictor of VTE, marker of hidden cancer in patients with idiopathic VTE, or even as an independent prognostic factor of response to chemotherapy and survival. In this review, the current evidence supporting the use of DD in cancer patients is critically exposed and discussed (AU)
Subject(s)
Humans , Fibrin Modulating Agents/analysis , Neoplasms/pathology , Hemostatic Disorders/physiopathology , Biomarkers, Tumor/analysis , Pulmonary Embolism/physiopathologyABSTRACT
There is a well-known close relationship between cancer and the haemostatic system. Plasma D-dimer (DD) is a marker of fibrin generation and lysis. In the clinical practice, its main use is in the diagnostic algorithms of venous thromboembolism (VTE), and it is one of the diagnostic criteria of disseminated intravacular coagulation. In patients with cancer, the specificity of DD is lower than in the general population, reducing its usefulness. However, there is a growing evidence that points out a possible application of DD in the clinical management of cancer patients as a predictor of VTE, marker of hidden cancer in patients with idiopathic VTE, or even as an independent prognostic factor of response to chemotherapy and survival. In this review, the current evidence supporting the use of DD in cancer patients is critically exposed and discussed.
